Akebia Therapeutics Inc
AKBA3.685USD
-0.035-0.95%
交易中 （美东）报价延迟15分钟
964.08M总市值
亏损市盈率 TTM
关于 Akebia Therapeutics Inc 公司
Akebia Therapeutics, Inc. 是一家完全整合的生物制药公司。该公司专注于开发和商业化治疗药物。该公司的产品组合和基于缺氧诱导因子 (HIF) 的产品线包括 Auryxia（柠檬酸铁）、Vafseo（vadadustat）、AKB-9090 和 AKB-10108。Auryxia（柠檬酸铁）是一种口服药物，已在美国获批并上市，用于两种适应症：控制透析依赖性慢性肾病 (DD-CKD) 成人患者的血清磷水平，以及治疗非透析依赖性慢性肾病 (NDD-CKD) 成人患者的缺铁性贫血 (IDA)。Vafseo（vadadustat）是一种 HIF 脯氨酰羟化酶 (HIF-PH) 抑制剂，已在 36 个国家获批用于治疗因慢性肾病 (CKD) 引起的贫血。它利用第三方进行 Auryxia 的商业分销，包括批发分销商和某些专业药房供应商。
公司简介
公司代码AKBA
公司名称Akebia Therapeutics Inc
上市日期Mar 20, 2014
CEOMr. John P. Butler
员工数量181
证券类型Ordinary Share
年结日Mar 20
公司地址245 First Street
城市CAMBRIDGE
上市交易所NASDAQ Capital Market Consolidated
国家United States of America
邮编02142
电话16178712098
网址https://akebia.com/
公司代码AKBA
上市日期Mar 20, 2014
CEOMr. John P. Butler
公司高管
名称
名称/职务
职务
持股
持股变动
Mr. John P. Butler
Mr. John P. Butler
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
1.68M
-17.18%
Mr. Adrian Adams
Mr. Adrian Adams
Independent Chairman of the Board
Independent Chairman of the Board
170.50K
+26.48%
Mr. Michael W. Rogers
Mr. Michael W. Rogers
Independent Director
Independent Director
131.73K
+37.18%
Ms. Cynthia Smith
Ms. Cynthia Smith
Independent Director
Independent Director
130.93K
+37.49%
Dr. Steven C. Gilman, Ph.D.
Dr. Steven C. Gilman, Ph.D.
Independent Director
Independent Director
122.83K
+40.97%
Dr. Myles Wolf, M.D.
Dr. Myles Wolf, M.D.
Independent Director
Independent Director
103.38K
+52.75%
Ms. Leanne M. Zumwalt
Ms. Leanne M. Zumwalt
Independent Director
Independent Director
79.40K
+81.69%
Mr. Nicholas (Nik) Grund
Mr. Nicholas (Nik) Grund
Senior Vice President, Chief Commercial Officer
Senior Vice President, Chief Commercial Officer
45.48K
-89.72%
Mr. Erik Ostrowski
Mr. Erik Ostrowski
Senior Vice President, Chief Financial Officer, Chief Business Officer, Treasurer
Senior Vice President, Chief Financial Officer, Chief Business Officer, Treasurer
--
-100.00%
Dr. Steven K. Burke, M.D.
Dr. Steven K. Burke, M.D.
Senior Vice President - Research and Development, Chief Medical Officer
Senior Vice President - Research and Development, Chief Medical Officer
--
--
查看更多
名称
名称/职务
职务
持股
持股变动
Mr. John P. Butler
Mr. John P. Butler
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
1.68M
-17.18%
Mr. Adrian Adams
Mr. Adrian Adams
Independent Chairman of the Board
Independent Chairman of the Board
170.50K
+26.48%
Mr. Michael W. Rogers
Mr. Michael W. Rogers
Independent Director
Independent Director
131.73K
+37.18%
Ms. Cynthia Smith
Ms. Cynthia Smith
Independent Director
Independent Director
130.93K
+37.49%
Dr. Steven C. Gilman, Ph.D.
Dr. Steven C. Gilman, Ph.D.
Independent Director
Independent Director
122.83K
+40.97%
Dr. Myles Wolf, M.D.
Dr. Myles Wolf, M.D.
Independent Director
Independent Director
103.38K
+52.75%
收入明细
暂无数据
暂无数据
业务
地区
暂无数据
股东统计
更新时间: 7月31日 周四
更新时间: 7月31日 周四
持股股东
股东类型
持股股东
持股股东
占比
BlackRock Institutional Trust Company, N.A.
5.32%
The Vanguard Group, Inc.
4.83%
State Street Global Advisors (US)
2.59%
Alerce Investment Management, L.P.
2.19%
Satter Muneer A
2.19%
Other
82.88%
持股股东
持股股东
占比
BlackRock Institutional Trust Company, N.A.
5.32%
The Vanguard Group, Inc.
4.83%
State Street Global Advisors (US)
2.59%
Alerce Investment Management, L.P.
2.19%
Satter Muneer A
2.19%
Other
82.88%
股东类型
持股股东
占比
Investment Advisor
13.32%
Investment Advisor/Hedge Fund
10.58%
Hedge Fund
9.31%
Individual Investor
3.61%
Research Firm
2.48%
Private Equity
2.19%
Bank and Trust
0.14%
Pension Fund
0.04%
Insurance Company
0.03%
Other
58.30%
机构持股
更新时间: 7月1日 周二
更新时间: 7月1日 周二
报告期
机构数
持股数
持股占比
持股变动
2025Q2
281
109.59M
41.73%
+26.45M
2025Q1
280
111.54M
42.50%
+30.68M
2024Q4
258
78.54M
36.08%
+7.41M
2024Q3
257
64.16M
30.51%
-2.18M
2024Q2
248
61.31M
29.27%
-7.52M
2024Q1
290
61.37M
29.36%
-12.30M
2023Q4
289
58.79M
31.24%
-20.79M
2023Q3
300
57.28M
30.45%
-25.18M
2023Q2
308
56.18M
30.22%
-26.52M
2023Q1
315
56.14M
30.23%
-26.40M
查看更多
股东持股明细
名称
持股数
占比
持股变动
变动比例
公告日期
BlackRock Institutional Trust Company, N.A.
13.97M
5.32%
+133.23K
+0.96%
Mar 31, 2025
The Vanguard Group, Inc.
12.69M
4.83%
+1.80M
+16.55%
Mar 31, 2025
State Street Global Advisors (US)
6.81M
2.59%
+501.11K
+7.95%
Mar 31, 2025
Alerce Investment Management, L.P.
5.75M
2.19%
--
--
Dec 31, 2024
Satter Muneer A
5.75M
2.19%
+5.75M
--
Dec 31, 2024
Geode Capital Management, L.L.C.
5.03M
1.92%
+235.65K
+4.91%
Mar 31, 2025
Great Point Partners, LLC
4.97M
1.89%
+4.97M
--
Mar 31, 2025
Renaissance Technologies LLC
4.01M
1.53%
+182.30K
+4.77%
Mar 31, 2025
Citadel Advisors LLC
3.65M
1.39%
+2.26M
+163.86%
Mar 31, 2025
Franklin Advisers, Inc.
2.67M
1.02%
+2.50M
+1495.36%
Mar 31, 2025
查看更多
持股ETF
更新时间: 8月2日 周六
更新时间: 8月2日 周六
机构名称
占比
ALPS Medical Breakthroughs ETF
0.65%
Invesco NASDAQ Future Gen 200 ETF
0.54%
Federated Hermes MDT Small Cap Core ETF
0.27%
SPDR S&P Biotech ETF
0.23%
iShares Micro-Cap ETF
0.21%
Goldman Sachs ActiveBeta US Small Cap Equity ETF
0.14%
Direxion Daily S&P Biotech Bull 3X Shares
0.13%
Fidelity Enhanced Small Cap ETF
0.13%
iShares Russell 2000 Value ETF
0.06%
Global X Russell 2000 ETF
0.04%
查看更多
ALPS Medical Breakthroughs ETF
占比0.65%
Invesco NASDAQ Future Gen 200 ETF
占比0.54%
Federated Hermes MDT Small Cap Core ETF
占比0.27%
SPDR S&P Biotech ETF
占比0.23%
iShares Micro-Cap ETF
占比0.21%
Goldman Sachs ActiveBeta US Small Cap Equity ETF
占比0.14%
Direxion Daily S&P Biotech Bull 3X Shares
占比0.13%
Fidelity Enhanced Small Cap ETF
占比0.13%
iShares Russell 2000 Value ETF
占比0.06%
Global X Russell 2000 ETF
占比0.04%
分红派息
近5年累计派现
0.00
美元
公告日期
分红计划
股权登记日
现金发放日
除权除息日
暂无数据
拆合股
公告日期
类型
比率
暂无数据
公告日期
类型
比率
暂无数据
